Last updated: 2 October 2026. Informational only, not medical advice.
CBD and methadone or buprenorphine, medications used in opioid use disorder treatment, carry a meaningful interaction consideration through the CYP3A4 pathway, alongside the additive sedation risk relevant to opioids generally. This is a particularly important category to get right given how carefully these treatment programs are managed and the seriousness of disrupting recovery-focused medication stability.
CBD and OUD treatment medications at a glance
| Medication | Primary pathway | Interaction relevance |
|---|---|---|
| Methadone | CYP3A4, CYP2B6 | Moderate to high |
| Buprenorphine | CYP3A4 | Moderate to high |
Why this category deserves particular care
Medication-assisted treatment for opioid use disorder is carefully dosed and monitored specifically to manage withdrawal, cravings, and stability in recovery. Both methadone and buprenorphine are significantly metabolized through CYP3A4, the same pathway CBD inhibits, meaning CBD could plausibly raise blood levels of either medication. Combined with the additive sedation concern relevant to opioid-class medications generally, this is a combination that needs the direct involvement of the treatment program managing your care, not a self-directed decision.
Why disclosure matters especially here
Addiction treatment programs are generally set up to support open communication about substance use, including supplements, precisely because unexpected interactions can complicate recovery in ways that are hard to interpret without full information. If you’re in methadone or buprenorphine treatment and interested in CBD for any reason, sleep, anxiety, or otherwise, discussing this openly with your treatment provider is both medically important and consistent with how these programs are designed to work.
What could happen if levels are affected
- Increased sedation, which for medications already carrying some sedative effect could become more pronounced
- Potentially altered treatment stability if blood levels shift meaningfully in either direction
- Complicated interpretation of any new symptoms, since it may be unclear whether they reflect a medication level change or something else
Practical guidance
- Disclose CBD use to your treatment program before starting, not after
- Expect your treatment team to want to monitor more closely if you do use CBD, this is a reasonable and appropriate response, not a punitive one
- Never adjust your methadone or buprenorphine dose or timing based on CBD use without your treatment team’s involvement
- Be honest about frequency and amount of any CBD use, accurate information helps your treatment team manage your care appropriately
Who this applies to most directly
- Anyone in methadone maintenance treatment. Discuss any CBD interest directly with your treatment program.
- Anyone on buprenorphine (including combination products). Same guidance applies.
- Early in treatment or recently adjusted dose. Stability isn’t established yet; additional variables complicate this period further.
Frequently asked questions
Can I use CBD while in methadone or buprenorphine treatment?
Possibly, but only with your treatment program’s knowledge and guidance, given the interaction potential and the importance of treatment stability.
Will my treatment program judge me for asking about CBD?
These programs are generally designed to support open communication about substance use and supplements; disclosure is viewed as part of appropriate care, not something to hide.
Could CBD affect how methadone or buprenorphine works?
Plausibly, through shared liver enzyme pathways that could raise medication levels, which is exactly why this needs direct medical oversight rather than self-management.
What if I already used CBD without telling my treatment team?
Inform them as soon as possible; accurate, current information helps them manage your care appropriately going forward.
